Lincoln Pharma in pink of health after incorporating subsidiary

Image
Capital Market
Last Updated : Oct 18 2017 | 2:28 PM IST

Lincoln Pharmaceuticals gained 1.71% to Rs 193 at 14:00 IST on BSE after the company said that it has incorporated wholly owned subsidiary company, Savebux Finance & Investment in India.

The announcement was made during market hours today, 18 October 2017.

Meanwhile, the BSE Sensex was up 40.11 points, or 0.12%, to 32,649.27. The BSE Small-Cap index was up 40.32 points, or 0.24%, to 17,106.47, outperforming the Sensex.

On the BSE, 12,292 shares were traded in the counter so far, compared with an average volume of 17,934 shares in the past one quarter. The stock had hit a high of Rs 195 and a low of Rs 187.60 so far during the day. The stock had hit a 52-week high of Rs 256.20 on 29 March 2017. The stock had hit a 52-week low of Rs 148 on 11 August 2017.

The stock had outperformed the market over the past one month till 17 October 2017, gaining 20.02% compared with 1.04% gains in the Sensex. The scrip had, however, underperformed the market in past one quarter, declining 1.33% as against Sensex's 1.67% rise. The scrip had also underperformed the market in past one year, dropping 16.63% as against Sensex's 18.45% rise.

The small-cap company has an equity capital of Rs 16.31 crore. Face value per share is Rs 10.

Savebux Finance & Investment has been incorporated with an object to carry out non-banking financial institution (NBFI) activities and the company is yet to commence its business operations.

The subsidiary will be required to obtain the approvals from the Reserve Bank of India and such other competent authorities as may be necessary. The subsidiary will have paid up capital of Rs 2 crore.

On a consolidated basis, net profit of Lincoln Pharmaceuticals fell 56.9% to Rs 4.91 crore on 51.3% rise in net sales to Rs 134.86 crore in Q1 June 2017 over Q1 June 2016.

Ahmedabad-based Lincoln Pharmaceuticals is engaged in manufacturing and exporting pharmaceuticals formulations under various therapeutic product group.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 18 2017 | 2:07 PM IST

Next Story